BACKGROUND: Healthcare-associated pneumonia (HCAP) is an entity distinct from community-acquired pneumonia (CAP). HCAP has a higher case-fatality rate, due either to HCAP organisms or to the health status of HCAP patients. The contribution of HCAP criteria to case-fatality rate is unknown. METHODS: We conducted a retrospective review of adult patients admitted with a diagnosis of pneumonia from July 2007 through November 2011 to 491 US hospitals. HCAP was defined as having at least 1 of the following: prior hospitalization within 90 days, hemodialysis, admission from a skilled nursing facility, or immune suppression. We compared characteristics of patients with CAP and patients with HCAP and explored the contribution of HCAP criteria to case-fatality rate in a hierarchical generalized linear model. RESULTS: Of 436,483 patients hospitalized with pneumonia, 149,963 (34.4%) had HCAP. Compared to CAP patients, HCAP patients were older, had more comorbidities, and were more likely to require intensive care unit (ICU) care. In-hospital case-fatality rate was higher among patients with HCAP, compared to those with CAP (11.1% vs 5.1%, P < .001). After adjustment for demographics, comorbidities, presence of other infections, early ICU admission, chronic and acute medications, early tests and therapies, and length of stay, HCAP remained associated with increased case-fatality rate (odds ratio [OR], 1.35 [95% confidence interval (CI), 1.32-1.39]); odds of death increased for each additional HCAP criterion (OR [95% CI]: 1 criterion, 1.27 [1.23-1.31], 2 criteria, 1.55 [1.49-1.62], and 3 or more criteria, 1.88 [1.72-2.06]). CONCLUSIONS: After adjustment for differences in patient characteristics, HCAP was associated with greater case-fatality rate than CAP. This difference may be due to HCAP organisms or to HCAP criteria themselves.
BACKGROUND:Healthcare-associated pneumonia (HCAP) is an entity distinct from community-acquired pneumonia (CAP). HCAP has a higher case-fatality rate, due either to HCAP organisms or to the health status of HCAPpatients. The contribution of HCAP criteria to case-fatality rate is unknown. METHODS: We conducted a retrospective review of adult patients admitted with a diagnosis of pneumonia from July 2007 through November 2011 to 491 US hospitals. HCAP was defined as having at least 1 of the following: prior hospitalization within 90 days, hemodialysis, admission from a skilled nursing facility, or immune suppression. We compared characteristics of patients with CAP and patients with HCAP and explored the contribution of HCAP criteria to case-fatality rate in a hierarchical generalized linear model. RESULTS: Of 436,483 patients hospitalized with pneumonia, 149,963 (34.4%) had HCAP. Compared to CAPpatients, HCAPpatients were older, had more comorbidities, and were more likely to require intensive care unit (ICU) care. In-hospital case-fatality rate was higher among patients with HCAP, compared to those with CAP (11.1% vs 5.1%, P < .001). After adjustment for demographics, comorbidities, presence of other infections, early ICU admission, chronic and acute medications, early tests and therapies, and length of stay, HCAP remained associated with increased case-fatality rate (odds ratio [OR], 1.35 [95% confidence interval (CI), 1.32-1.39]); odds of death increased for each additional HCAP criterion (OR [95% CI]: 1 criterion, 1.27 [1.23-1.31], 2 criteria, 1.55 [1.49-1.62], and 3 or more criteria, 1.88 [1.72-2.06]). CONCLUSIONS: After adjustment for differences in patient characteristics, HCAP was associated with greater case-fatality rate than CAP. This difference may be due to HCAP organisms or to HCAP criteria themselves.
Authors: Tara Lagu; Peter K Lindenauer; Michael B Rothberg; Brian H Nathanson; Penelope S Pekow; Jay S Steingrub; Thomas L Higgins Journal: Crit Care Med Date: 2011-11 Impact factor: 7.598
Authors: James D Chalmers; Joanne K Taylor; Aran Singanayagam; Gillian B Fleming; Ahsan R Akram; Pallavi Mandal; Gourab Choudhury; Adam T Hill Journal: Clin Infect Dis Date: 2011-07-15 Impact factor: 9.079
Authors: Marin H Kollef; Lee E Morrow; Robert P Baughman; Donald E Craven; John E McGowan; Scott T Micek; Michael S Niederman; David Ost; David L Paterson; John Segreti Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: Annastazia E Learoyd; Lisa Woodhouse; Laurence Shaw; Nikola Sprigg; Daniel Bereczki; Eivind Berge; Valeria Caso; Hanne Christensen; Ronan Collins; Anna Czlonkowska; Anwar El Etribi; Tracy D Farr; John Gommans; Ann-Charlotte Laska; George Ntaios; Serefnur Ozturk; Stuart J Pocock; Kameshwar Prasad; Joanna M Wardlaw; Kevin C Fone; Philip M Bath; Rebecca C Trueman Journal: Transl Stroke Res Date: 2017-07-27 Impact factor: 6.829
Authors: Mihaela S Stefan; Aruna Priya; Penelope S Pekow; Tara Lagu; Jay S Steingrub; Nicholas S Hill; Brian H Nathanson; Peter K Lindenauer Journal: J Crit Care Date: 2017-05-23 Impact factor: 3.425
Authors: Brandon J Webb; Eddie Stenehjem; Kristin Dascomb; Mark Metersky; Holenarasipur R Vikram; Nathan C Dean Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Harshad Hegde; Ingrid Glurich; Aloksagar Panny; Jayanth G Vedre; Jeffrey J VanWormer; Richard Berg; Frank A Scannapieco; Jeffrey Miecznikowski; Amit Acharya Journal: Methods Inf Med Date: 2022-03-17 Impact factor: 1.800
Authors: Thomas P Lodise; Weihong Fan; David C Griffith; Michael N Dudley; Katherine A Sulham Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr Journal: Antimicrob Resist Infect Control Date: 2017-12-06 Impact factor: 4.887
Authors: Damon P Eisen; Karin Leder; Robyn L Woods; Jessica E Lockery; Sarah L McGuinness; Rory Wolfe; David Pilcher; Elizabeth M Moore; Adithya Shastry; Mark R Nelson; Christopher M Reid; John J McNeil; Emma S McBryde Journal: Lancet Respir Med Date: 2020-09-17 Impact factor: 30.700